# Immune Evasion Resistance Report - Leukemia

## Summary

Total epitopes analyzed: 4
Evasion-resistant epitopes (score > 0.6): 4
High-risk epitopes (susceptibility > 0.7): 0
Average resistance score: 0.660
Average evasion susceptibility: 0.033

## Leukemia Immune Evasion Profile

**Primary Evasion Mechanisms:**
- MHC Class I downregulation
- Immunosuppressive microenvironment
- Regulatory T-cell suppression

**Microenvironment:** immunosuppressive
**Checkpoint Pathways:** pd1_pdl1, ctla4

## Top 15 Evasion-Resistant Epitopes

| Rank | Peptide | Resistance Score | Susceptibility | Conservation | Mutation Freq |
|------|---------|------------------|----------------|--------------|---------------|
| 1 | SLYNTVATL | 0.684 | 0.063 | 0.662 | 0.102 |
| 2 | GILGFVFTL | 0.674 | 0.013 | 0.483 | 0.113 |
| 3 | YLQPRTFLL | 0.652 | 0.015 | 0.692 | 0.102 |
| 4 | KIADYNYKL | 0.629 | 0.041 | 0.575 | 0.102 |

## Evasion Mechanism Analysis

### MHC Class I downregulation

- Susceptible epitopes: 4
- Resistant epitopes: 0
- Recommended resistance strategies: mhc_ii_targeting, nk_cell_activation

### Immunosuppressive microenvironment

- Susceptible epitopes: 1
- Resistant epitopes: 3
- Recommended resistance strategies: checkpoint_inhibitors, adjuvants

### Regulatory T-cell suppression

- Susceptible epitopes: 0
- Resistant epitopes: 4
- Recommended resistance strategies: treg_depletion, th1_polarization

## Vaccine Strategy Recommendations

### Primary Epitopes (4 selected)

1. YLQPRTFLL (Resistance: 0.652)
2. KIADYNYKL (Resistance: 0.629)
3. SLYNTVATL (Resistance: 0.684)
4. GILGFVFTL (Resistance: 0.674)

### Recommended Adjuvants

**TLR_agonist**
- Examples: CpG_ODN, Poly_IC, LPS
- Mechanism: Overcome immunosuppression via innate immune activation

**Th1_polarizing**
- Examples: IL-12, IFN-gamma, CFA
- Mechanism: Promote Th1 responses and reduce Treg activity

**checkpoint_inhibitor**
- Examples: anti-PD1, anti-PDL1, anti-CTLA4
- Mechanism: Block inhibitory checkpoint pathways

### Combination Therapy Recommendations

**vaccine_plus_checkpoint_inhibition**
- Components: vaccine, anti-PD1, anti-CTLA4
- Rationale: Enhance T-cell activation and overcome exhaustion

**vaccine_plus_adoptive_transfer**
- Components: vaccine, CAR-T, TIL
- Rationale: Combine active and passive immunotherapy

### Delivery Optimization

- Route: intramuscular
- Formulation: mhc_ii_targeting
- Timing: prime_boost

## Key Recommendations

Limited evasion-resistant epitopes. Strongly recommend combination with checkpoint inhibitors and adjuvants.

Implementation priorities:
1. Focus on epitopes with resistance score > 0.6
2. Implement recommended combination therapies
3. Use appropriate adjuvants for disease-specific evasion mechanisms
4. Consider optimized delivery strategies
5. Plan for monitoring of immune escape variants
6. Validate resistance predictions in relevant disease models
